AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects - JMAD
Study identifier:D3190C00015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Single-center, Single-blind, Randomized, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Oral Doses of AZD1305 Extended-release Capsules in Healthy Male Japanese and Caucasian Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1305, Placebo
Sex
Male
Actual Enrollment
45
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Jul 2009
Primary Completion Date: 01 Nov 2009
Study Completion Date: 01 Nov 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1, AZD1305 | Drug: AZD1305 single and multiple oral doses, extended-release capsule |
| Placebo Comparator: 2, Placebo | Drug: Placebo single and multiple oral doses, capsule |
Contacts
Investigators
Principal Investigator
Mark Yen
California Clinical Trials
